Nuwellis (NUWE) Competitors $1.00 -0.01 (-0.99%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends NUWE vs. MBOT, NRXS, NEPH, LUCY, IINN, LFWD, MHUA, SSKN, LYRA, and PYPDShould you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Microbot Medical (MBOT), NeurAxis (NRXS), Nephros (NEPH), Innovative Eyewear (LUCY), Inspira Technologies Oxy B.H.N. (IINN), ReWalk Robotics (LFWD), Meihua International Medical Technologies (MHUA), STRATA Skin Sciences (SSKN), Lyra Therapeutics (LYRA), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry. Nuwellis vs. Microbot Medical NeurAxis Nephros Innovative Eyewear Inspira Technologies Oxy B.H.N. ReWalk Robotics Meihua International Medical Technologies STRATA Skin Sciences Lyra Therapeutics PolyPid Microbot Medical (NASDAQ:MBOT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Which has more volatility and risk, MBOT or NUWE? Microbot Medical has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Do analysts recommend MBOT or NUWE? Microbot Medical currently has a consensus target price of $7.00, indicating a potential upside of 621.65%. Nuwellis has a consensus target price of $17.00, indicating a potential upside of 1,600.00%. Given Nuwellis' stronger consensus rating and higher possible upside, analysts plainly believe Nuwellis is more favorable than Microbot Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Microbot Medical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuwellis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has better earnings and valuation, MBOT or NUWE? Microbot Medical has higher earnings, but lower revenue than Nuwellis. Microbot Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMicrobot MedicalN/AN/A-$10.74M-$0.80-1.21Nuwellis$8.97M0.49-$20.21M-$116.41-0.01 Does the media favor MBOT or NUWE? In the previous week, Nuwellis had 3 more articles in the media than Microbot Medical. MarketBeat recorded 4 mentions for Nuwellis and 1 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in MBOT or NUWE? 16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 10.5% of Microbot Medical shares are owned by company insiders. Comparatively, 2.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor MBOT or NUWE? Microbot Medical received 325 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 70.67% of users gave Microbot Medical an outperform vote while only 53.66% of users gave Nuwellis an outperform vote. CompanyUnderperformOutperformMicrobot MedicalOutperform Votes34770.67% Underperform Votes14429.33% NuwellisOutperform Votes2253.66% Underperform Votes1946.34% Is MBOT or NUWE more profitable? Microbot Medical has a net margin of 0.00% compared to Nuwellis' net margin of -169.54%. Microbot Medical's return on equity of -218.30% beat Nuwellis' return on equity.Company Net Margins Return on Equity Return on Assets Microbot MedicalN/A -218.30% -158.17% Nuwellis -169.54%-28,159.25%-207.24% SummaryMicrobot Medical beats Nuwellis on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Nuwellis News Delivered to You Automatically Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUWE vs. The Competition Export to ExcelMetricNuwellisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.37M$3.07B$5.14B$9.08BDividend YieldN/A1.75%5.09%4.23%P/E Ratio-0.0117.1690.1317.19Price / Sales0.4950.221,116.25117.01Price / CashN/A39.9143.1037.85Price / Book0.053.724.784.78Net Income-$20.21M$89.83M$120.31M$225.60M7 Day Performance-15.25%-1.76%-1.92%-1.23%1 Month Performance-17.36%-1.47%13.65%0.46%1 Year Performance-95.17%-0.54%28.34%15.24% Nuwellis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUWENuwellis1.6403 of 5 stars$1.00-1.0%$17.00+1,600.0%-95.0%$4.37M$8.97M-0.0159News CoveragePositive NewsMBOTMicrobot Medical1.9092 of 5 stars$1.01+0.9%$7.00+593.5%-29.2%$17.09MN/A-1.2520NRXSNeurAxisN/A$2.43-2.0%N/A+5.3%$16.96M$2.46M-1.3519Gap DownNEPHNephros1.6901 of 5 stars$1.54-0.6%$5.00+224.7%-47.6%$16.24M$13.55M-17.2230Positive NewsLUCYInnovative Eyewear1.7076 of 5 stars$6.39+4.6%$20.00+213.0%-32.6%$15.60M$1.56M-0.639IINNInspira Technologies Oxy B.H.N.0.3106 of 5 stars$1.12-4.3%N/A-21.9%$14.14MN/A0.0020LFWDReWalk Robotics3.3589 of 5 stars$1.54-6.7%$13.00+744.2%N/A$13.56M$25.00M-0.6260Positive NewsHigh Trading VolumeMHUAMeihua International Medical Technologies0.6856 of 5 stars$0.51+2.3%N/A-86.4%$12.85M$94.25M0.00620Gap DownSSKNSTRATA Skin Sciences1.0225 of 5 stars$2.99-0.3%N/A-51.5%$12.47M$32.68M-1.11120Positive NewsLYRALyra Therapeutics2.4053 of 5 stars$0.19+2.7%$4.50+2,298.7%-96.1%$12.28M$1.47M-0.1250Gap DownPYPDPolyPid2.3304 of 5 stars$2.44-6.5%$12.00+391.8%-17.6%$11.71MN/A-0.3080Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies MBOT Alternatives NRXS Alternatives NEPH Alternatives LUCY Alternatives IINN Alternatives LFWD Alternatives MHUA Alternatives SSKN Alternatives LYRA Alternatives PYPD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NUWE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
